^
BIOMARKER:

AR-V7 overexpression

AR-V7 overexpression
Prostate Cancer
enzalutamide
Resistant: C3 – Early Trials
AR-V7 overexpression
Prostate Cancer
abiraterone acetate
Resistant: C3 – Early Trials